Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
TD Cowen Starts Maze Therapeutics (MAZE) at Buy
February 25, 2025 5:30 AM ESTTD Cowen analyst Tyler Van Buren initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating.
The analyst comments "MZE829 (oral APOL1 inhibitor) could address the majority of >1M AKD patients and is ~100x more potent than Vertex's inaxaplin. MZE782 (novel oral... More
Guggenheim Starts Maze Therapeutics (MAZE) at Buy
February 25, 2025 12:59 AM ESTGuggenheim analyst Debjit Chattopadhyay initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating and a price target of $19.00.
The analyst comments: "Leveraging the companys Compass platform, mgmt has advanced three small molecules into clinical development. These investigational medicines engage genetic targets... More
JPMorgan Starts Maze Therapeutics (MAZE) at Overweight
February 25, 2025 12:58 AM ESTJPMorgan analyst Anupam Rama initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Overweight rating and a price target of $30.00.
The analyst comments: "The companys proprietary COMPASS platform has produced multiple shots on goal to date. Indeed, lead asset MZE829 (APOL1 inhibitor) in APOL1 kidney disease (AKD) is currently in a phase 2 study, with initial or first top-line data from one of the three cohorts... More
